Biological Determinants of HRQL and pain in myeloma
Research type
Research Study
Full title
BIOLOGICAL DETERMINANTS OF HEALTH RELATED QUALITY OF LIFE AND PAIN IN MYELOMA: AN EXPLORATORY STUDY IN ASSOCIATION WITH THE MYELOMA X RELAPSE (INTENSIVE) TRIAL
IRAS ID
191014
Contact name
John Snowden
Contact email
Sponsor organisation
Sheffield Teaching Hospitals NHS Foundation Trust
Duration of Study in the UK
3 years, 1 months, 31 days
Research summary
Myeloma is a largely incurable cancer which requires recurrent rounds of chemotherapy from presentation and in relapse. Patients accumulate a burden of symptoms and side effects from the recurrent treatments for the relapses. The Myeloma X trial examined the role of intensive transplant treatment versus less intensive treatment in patients with relapsed myeloma. The trial proved benefits of intensive treatment in delaying relapse and prolonging survival but the intensity of treatment had adverse effects on Health Related Quality of Life (HRQoL). \n\nThis study aims to use the serum samples stored in the Myeloma X Trial to measure hormones and vitamins to identify factors that might correlate with HRQoL and symptoms and other laboratory data collected in the Myeloma X Trial. In this way we hope this exploratory study will identify potentially reversible or treatable factors which might improve the HRQoL in myeloma patients. Examples include screening to diagnose then correct of hormone disorders, or potentially identifying blood markers that may help with management of pain and other symptoms.
REC name
London - Brent Research Ethics Committee
REC reference
16/LO/2248
Date of REC Opinion
21 Dec 2016
REC opinion
Favourable Opinion